Experimental drugs designed to reduce the body's natural production of alpha-ketoglutarate slow tumor growth and increase lifespan in mouse models of DIPG.
Cancer treatment vaccine research leads to remission in a child with a relapsed neuroblastoma.
Scientists have long believed that glioblastoma multiforme, the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. Researchers found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.
Researchers have discovered two gene variants that raise the risk of the pediatric cancer neuroblastoma. This is the first study to link known cancer-related genes HACE1 and LIN28B to neuroblastoma. The study broadens understanding of how gene changes may make a child susceptible to this early childhood cancer, as well as causing a tumor to progress.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
